Axcrona Karol, Nilsson Rasmus, Brennhovd Bjørn, Sørebø Øystein, Fosså Sophie D, Dahl Alv A
Department of Urology, Akershus University Hospital, Lørenskog, Norway.
Department of Urology, Telemark Hospital, Skien, Norway.
BMC Urol. 2017 Dec 2;17(1):111. doi: 10.1186/s12894-017-0302-7.
Recently, the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26) was recommended for the assessment of adverse effects after the treatment of prostate cancer without clear reasons. This decision encouraged us to review the questionnaire development from the UCLA Prostate Cancer Index (UCLA-PCI) to the EPIC-16 CP with a focus on psychometric properties. We also reviewed PubMed for papers concerning such properties of the EPIC-26 since 2012 (latest review in 2011). Finally, we examined the psychometric properties of the EPIC-26 in a sample of Norwegian males treated with robot-assisted laparoscopic prostatectomy (RALP).
This study used three methods: (1) Comparison of the content of the UCLA-PCI, EPIC-50, EPIC-26, and EPIC-16 CP; (2) Review of EPIC-26 and EPIC-16 CP papers in PubMed from 2012 to 2016, identifying papers reporting on the psychometric properties of these questionnaires; and (3) Psychometric examination of the EPIC-26 rating in 651 Norwegian men treated with RALP at a mean of 3.2 years post-surgery.
The questionnaire development showed a significant increase in bother versus function items, and the EPIC-26 contains eight function and 18 bother items. Twelve papers concerning the EPIC-26 available on PubMed since 2012 support the psychometric properties of the EPIC-26. The Norwegian EPIC-26 findings supported the psychometric properties of the EPIC-26, but suggested six subdomains both by exploratory and confirmatory factor analyses.
In general our examinations supported the adequate psychometric properties of the EPIC-26, although the factor structure, construct and predictive validity of the instrument should be examined further.
最近,扩展前列腺癌指数综合26项版本(EPIC - 26)被推荐用于评估前列腺癌治疗后的不良反应,但原因不明。这一决定促使我们回顾从加州大学洛杉矶分校前列腺癌指数(UCLA - PCI)到EPIC - 16 CP的问卷发展情况,重点关注心理测量学特性。我们还检索了自2012年以来(2011年的最新综述)PubMed上关于EPIC - 26此类特性的论文。最后,我们在接受机器人辅助腹腔镜前列腺切除术(RALP)治疗的挪威男性样本中检验了EPIC - 26的心理测量学特性。
本研究采用了三种方法:(1)比较UCLA - PCI、EPIC - 50、EPIC - 26和EPIC - 16 CP的内容;(2)回顾2012年至2016年PubMed上关于EPIC - 26和EPIC - 16 CP的论文,识别报告这些问卷心理测量学特性的论文;(3)对651名接受RALP治疗的挪威男性在术后平均3.2年时进行EPIC - 26评分的心理测量学检验。
问卷发展显示,困扰项目与功能项目相比显著增加,EPIC - 26包含8个功能项目和18个困扰项目。自2012年以来,PubMed上有12篇关于EPIC - 26的论文支持其心理测量学特性。挪威EPIC - 26的研究结果支持其心理测量学特性,但探索性和验证性因素分析均表明有六个子领域。
总体而言,我们的检验支持EPIC - 26具有足够的心理测量学特性,尽管该工具的因素结构、构想和预测效度应进一步检验。